Issue 6/2023
Content (10 Articles)
Malaria Vaccines: Progress to Date
Danielle I. Stanisic, Michael F. Good
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies
Parul Berry, Sahil Khanna
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
Khaled Sanber, Samuel Rosner, Patrick M. Forde, Kristen A. Marrone
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical
Javiera Miranda, Nicolás Lefin, Jorge F. Beltran, Lisandra Herrera Belén, Argyro Tsipa, Jorge G. Farias, Mauricio Zamorano
Treatment with Biologic Drugs in Pediatric Behçet’s Disease: A Comprehensive Analysis of the Published Data
Ezgi Deniz Batu, Seher Sener, Veysel Cam, Nuray Aktay Ayaz, Seza Ozen
Patients’ Perceptions of Biosimilars: A Systematic Review
Qiyou Wu, Zhitao Wang, Xin Wang, Hui Yu, Jing Sun
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Yu-Chien Tsao, Ting-Ying Chen, Li-An Wang, Chia-Chun Lee, Wan-Ju Annabelle Lee, Sheng-Min Hsu, Chi-Chun Lai, Shih-Chieh Shao, Jia-Horung Hung, Edward Chia-Cheng Lai
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
Nadine Kirsch-Stefan, Elena Guillen, Niklas Ekman, Sean Barry, Verena Knippel, Sheila Killalea, Martina Weise, Elena Wolff-Holz
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
Ulf Müller-Ladner, Axel Dignass, Karl Gaffney, Deepak Jadon, Marco Matucci-Cerinic, Triana Lobaton, Philippe Carron, Javier P. Gisbert, Ira Pande, Maximilian Utzinger, Janet Addison
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer
Catherine Pham, Fang Niu, Thomas Delate, Gary L. Buchschacher Jr, Yan Li, Ekim Ekinci, Kim Le, Rita L. Hui